Loading
NASDAQHealthcareBiotechnology
Latest quote
$45.54
+$1.14 · +2.57%
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Previous close
$45.54
+$1.14 · +2.57%
Pre-market
$45.018
−$0.522 · -1.15%
Oct 9, 8:33 AM ET
Regular session · ET · Market data may be delayed.
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Day range
Current $45.54
52-week range
Current $45.54
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
44
Fair Value
Sentiment
63
Bullish
Risk
88
Extreme Risk
Momentum
23
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Day range
Current $45.54
52-week range
Current $45.54
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 4.91M USD | 10.09M USD | — | — |
| Gross profit | — | 4.91M USD | 10.09M USD | — | — |
| Research and development | 19.52M USD | 46.42M USD | 49.43M USD | 35.2M USD | 30.7M USD |
| Selling, general, and administrative | 16.99M USD | 14.64M USD | 12.65M USD | 12.09M USD | 11.37M USD |
| Operating expenses | 36.51M USD | 61.06M USD | 62.08M USD | 47.28M USD | 42.07M USD |
| Interest income | 1.14M USD | 3.42M USD | 4.56M USD | 1.52M USD | 119K USD |
| Interest expense | 90K USD | 307K USD | 483K USD | 420K USD | 345K USD |
| Depreciation and amortization | 21K USD | 46K USD | 70K USD | 74K USD | 68K USD |
| Operating income | −36.51M USD | −56.15M USD | −51.99M USD | −47.28M USD | −42.07M USD |
| Net income | −38.97M USD | −53.04M USD | −47.92M USD | −46.18M USD | −42.29M USD |
Company facts updated Oct 9, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$140.6
208.74% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 5, 2025 | 1:75 | — | — |
Effective Aug 5, 2025
1:75
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.01M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM3.11M0.00%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF1.88M0.00%95.4B USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO919.76K0.01%18B USD0.06%$112.1-0.10%
iShares Micro-Cap ETFIWC346.28K0.03%1.32B USD0.60%$182.79-0.31%
iShares Russell 2000 Growth ETFIWO292.46K0.00%14.04B USD0.24%$353.47-0.53%
Dimensional - US Small Cap ETFDFAS180K0.00%33.8B USD0.31%$78.10+0.23%
Vanguard Russell 2000 Value ETFVTWV110.75K0.01%1.4B USD0.06%$186.06+0.59%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASVanguard Russell 2000 Value ETFVTWVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
